top of page
  • Recruiting

NCT04508790: Phase 2: Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of RRMM Myeloma

Updated: May 25, 2022

NCT04508790: Phase 2: Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma


leflunomide pom dex


Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma


This phase II trial studies how well leflunomide, pomalidomide, and dexamethasone work for the treatment of multiple myeloma that has come back (relapsed) or does not respond to treatment (refractory). Leflunomide may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunotherapy with pomalidomide, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving leflunomide with pomalidomide and dexamethasone may work better in treating multiple myeloma compared to pomalidomide and dexamethasone alone.


Sponsor

City of Hope Medical Center


Collaborator

National Cancer Institute (NCI)


Location

United States, California

 

ClinicalTrials.gov Identifier: NCT04508790


Official Title: A Phase 2 Trial of Leflunomide, Pomalidomide, and Dexamethasone for Relapsed/Refractory Multiple Myeloma


First Posted: August 11, 2020


Click here for details on ClinicalTrials.gov

 

Drug: Dexamethasone

Drug: Leflunomide

Drug: Pomalidomide

 

Leflunomide (Code C1128)

4-Isoxazolecarboxamide, 5-Methyl-N-(4-(trifluoromethyl)phenyl)-

Arava

Leflunomide

LEFLUNOMIDE

leflunomide

SU101

 

Location

United States, California


Comments


Posts Archive
bottom of page